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The FIP1L1-PDGFRA rearrangement results in constitutive activation of the tyrosine kinase PDGFRA. Neoplasms harboring
this rearrangement are responsive to imatinib mesylate at doses much lower than those recommended for the treatment
of chronic myelogenous leukemia. Only a single report has described the identification of FIP1L1-PDGFRA in chronic
myelomonocytic leukemia (CMML). Herein, we present a case report of a patient in whom the FIP1L1-PDGFRA was
discovered as he evolved from CMML to acute myeloid leukemia (AML). The presence of a dominant neoplastic clone
with FIP1L1-PDGFRA rearrangement was suspected on the basis of sudden onset of peripheral and bone marrow
eosinophilia and confirmed by fluorescence in situ hybridization and molecular diagnostic tests. Whereas the patient was
initially refractory to chemotherapy before the rearrangement was detected, subsequent therapy with imatinib led to
complete remission.
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Hypereosinophilia is a feature of a variety of uncommon
hematologic disorders like hyperseosinophilic syndrome
(HES), systemic mastocytosis (SM) and chronic eosino-
philic leukemia (CEL). Approximately 4% of patients with
HES or SM have interstitial deletion of chromosome 4q12
leading to juxtaposition of FIP1L1 and PDGFRA [1]. The
fusion product is exquisitely sensitive to therapy with ima-
tinib mesylate, and hence its identification has important
therapeutic ramifications particularly in hematologic dis-
orders presenting with hypereosinophilia [2-5]. We herein
present the case of a patient in whom FIP1L1-PDGFRA
was discovered at the time of evolution from chronic mye-
lomonocytic leukemia (CMML) to refractory acute mye-
loid leukemia and how therapy with imatinib resulted in
durable complete remission.* Correspondence: jkhoury@mdanderson.org
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A 64-year-old Caucasian man presented to our institution
with a 6-month history of progressive leukocytosis. Per the
patient’s outside medical records, a bone marrow biopsy at
initial presentation had shown a 100% cellular marrow
with marked myeloid hyperplasia. Conventional cytogenet-
ics demonstrated a diploid male karyotype. Fluorescence
in situ hybridization studies (FISH) were negative for
myelodysplasia-associated abnormalities. Molecular studies
were negative for BCR-ABL rearrangement, and JAK2V617F
and MPL W515L mutations. Based on these features, he was
diagnosed with myelodysplastic/myeloproliferative neo-
plasm, unclassifiable, and was started on hydroxyurea, 1.5
grams daily. At presentation to our institution, his white
blood cell (WBC) count was 44.6 ×109/L with 76% neutro-
phils, 6% metamyelocytes, 10% monocytes, 6% lympho-
cytes, 1% eosinophils and 1% blasts, with absolute
monocytosis (4.46 × 109/L) and eosinophilia (0.45 × 109/L).
He was anemic (hemoglobin 9.0 g/dL) and mildly thrombo-
cytopenic (platelet count 119 × 109/L). He did not have
splenomegaly on physical examination. Bone marrow
evaluation performed at presentation to our institutiond. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Bone marrow core biopsy at the time of initial FIP1L1- PDGFRA rearrangement discovery. The bone marrow is hypercellular
(100%), with prominent eosinophilia and myeloid hyperplasia, mild increase in immature cells, and features of myelofibrosis manifesting primarily
as cellular streaming. (a: 10× objective; b: 20× objective; hematoxylin and eosin stain).
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hyperplasia. Megakaryocytes were decreased in number
and included rare dysplastic forms. Wright-Giemsa
stained smears prepared from the bone marrow aspirate
were remarkable for increased myeloid cells and triline-
age dysplasia; a 500-cell differential count showed
mildly increased monocytes (6%) and myeloid blasts
(7%). The constellation of findings was diagnostic of
chronic myelomonocytic leukemia (CMML-1). Conven-
tional cytogenetics showed trisomy 8 in two of twenty
analyzed metaphases; this was confirmed by fluores-
cence in situ hybridization (FISH) using an alpha-
satellite (D8Z2) CEP8 probe (positive in 4% of the cells
studied). Reverse transcriptase polymerase chain reaction
(RT-PCR) performed on the bone marrow aspirate was
negative for BCR-ABL fusion. Targeted next-generation se-
quencing mutation analysis was negative for 53 “hotspot”
mutations analyzed as described previously [6].
The patient was enrolled on the SGI-110 clinical trial, a
phase 1–2 dose escalation, multicenter study of SGI-110, a
DNA hypomethylating agent, in subjects with intermedi-
ate or high-risk myelodysplastic syndromes (MDS) or
AML. He received two courses of SGI-110, after which he
experienced rapidly progressive leukocytosis with a peak










Initial presentation 44.6 1, 0.45 1 7 CMML
After 2 months 65.1 9, 5.8 5 4 CMML
After 1 month 126 11, 13.8 16 12 Myelo
neopl
and P
After 1 month 6.4 1, 0.06 1 26 AML w
WBC: white blood cells, PB: peripheral blood, AEC: absolute eosinophil count, BM: b
myeloid leukemia.eosinophilia (11%). Bone marrow evaluation performed at
this time demonstrated nearly 100% cellularity with mye-
loid hyperplasia; in contrast to the previous biopsy, prom-
inent eosinophilia and moderate myelofibrosis were
noted in this sample (Figure 1a-b). Wright-Giemsa
stained smears showed increased granulocytes with left-
shifted maturation and prominent eosinophilia (16%) in
a background of trilineage dysplasia. There was no sig-
nificant increase in bone marrow monocytes (5%). Mye-
loid blasts comprised 12% of total nucleated cells. The
unexpected and abrupt presence of prominent eosino-
philia in the peripheral blood and bone marrow at this
point in time prompted us to evaluate for PDGFRA re-
arrangement. FISH analysis performed using a LSI-4q12 tri-
color rearrangement probe that hybridizes to the
chromosome 4q12 region containing the FIP1L1, CHIC2
and PDGFRA genes revealed deletion of the CHIC2 gene in
86.5% of the cells analyzed indicating the presence of the
FIP1L1-PDGFRA rearrangement. The FIP1L1-PDGFRA fu-
sion transcript was further confirmed by RT-PCR. Low-
level trisomy 8 was also detected by FISH in this sample.
Based on these findings a diagnosis of myelodysplastic/my-
eloproliferative neoplasm with eosinophilia and PDGFRA
rearrangement was rendered. A follow-up bone marrow bi-
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Table 2 PDGFRA rearrangement in unusual adult myeloid neoplasms
Author/journal Disease Treatment Outcome
Tang et al., Acta Haematol 2012;128:83–87 Myeloproliferative neoplasm
with eosinophilia
Imatinib – started at 400 mg daily
and maintained at 100 mg daily
Complete hematologic and molecular
remission at 12 months
Papanikolaou et al., Ann Hematol. 2012 May;91(5):785-7 Chronic eosinophilic leukemia with
lytic bone lesions
Imatinib 200 mg daily; on progression,
nilotinib 400 mg BID
Progressed to erythroblastoid blast
crisis after 2 years on TKI
Sorour et al., Br J Haematol. 2009 Jul;146(2):225-7 Acute myeloid leukemia
with eosinophilia
Imatinib with FLAG-Ida followed by
matched unrelated allograft
Relapsed with Imatinib resistance; started
on Dasatinib but died 15 months later
Lierman et al., Leukemia. 2009 May;23(5):845-51 Chronic eosinophilic leukemia
blast crisis with Imatinib resistance
Sorafenib 400 mg BID Hematologic response without
molecular response for 3 months
Zota et al., J Clin Oncol. 2008 Apr 20;26(12):2040-1 Chronic myelomonocytic leukemia Imatinib 400 mg BID Resolution of eosinophilia without
other hematologic response; progressed to
extramedullary disease
Florian et al., Leuk Res. 2006 Sep;30(9):1201-5 Systemic mastocytosis with chronic
eosinophilic leukemia
Incomplete response to hydroxyurea,
corticosteroids and interferon-alpha;
started on imatinib 100 mg in 2002
Long-term response to low-dose Imatinib
(50-100 mg) after inadequate responses
to previous therapies
Von Bubnoff et al., Leukemia. 2005 Feb;19(2):286-7 Chronic myeloproliferative disorder
with eosinophilia
Imatinib 100-400 mg daily Hematologic and symptomatic response for
6 months; progression to myeloid blasts crisis
and malignant pleural effusion
Saflet et al., Genes Chromosomes Cancer
2004 May;40(1):44-50
Atypical chronic myeloid leukemia
with t(4;22) leading to formation of
BCR-PDGFRA fusion gene




















Shah et al. Journal of Hematology & Oncology 2014, 7:26 Page 4 of 5
http://www.jhoonline.org/content/7/1/2626% blasts. In addition to persistent low-level trisomy 8,
conventional cytogenetics and FISH demonstrated a new
clone with TP53 gene deletion. FISH was positive for dele-
tion of the CHIC2 gene, TP53 deletion and trisomy 8 in
90%, 10% and 9% of the analyzed cells, respectively.
The patient was then started on imatinib mesylate
400 mg daily along with a short course of idarubucin and
subcutaneous cytarabine for cytoreduction. He achieved
complete hematologic and morphologic remission and
went on to receive a matched unrelated allogeneic stem cell
transplant (SCT). To date, the patient remains in complete
hematologic, morphologic and molecular remission with
successful engraftment as demonstrated by chimerism stud-
ies. The sequence of events is provided in Table 1.
Discussion
The PDGFRA and PDGFRB proteins are members of
the class III receptor kinase family that also includes c-
KIT, and FLT3 [7]. PDGFRA is located on chromosome
4q12 [8]. A small interstitial deletion of 4q12 leads to
juxtaposition of FIP1L1 and PDGFRA resulting in a gain
of function fusion protein with signal independent kin-
ase activity and therefore increased cell proliferation and
survival [9]. This interstitial deletion is generally cryptic
and not detectable using standard cytogenetic banding
techniques.
FIP1L1- PDGFRA rearrangements are often associated
with chronic eosinophilic leukemia and hypereosinophilic
syndromes [9,10] as well as systemic mastocytosis [11].
Pardanani et al. reported a prevalence of approximately
4% for FIP1L1- PDGFRA fusion gene in a large series of
patients with suspected or established HES or systemic
mastocysosis [1]. We recently described a case of chronic
neutrophilic leukemia associated with FIP1L1- PDGFRA
rearrangement [4]. The basis for the apparent lineage pre-
dilection of FIP1L1- PDGFRA for eosinophils is not well
understood. The hypothesis is that it is present in all mye-
loid lineages, but that eosinophils are particularly sensitive
to the FIP1L1- PDGFRA proliferative signal [12]. In con-
trast to rearrangements involving PDGFRB, the FIP1L1-
PDGFRA rearrangement is exceedingly rare in the setting
of chronic myelomonocytic leukemia [13-16]. To our
knowledge, only one other case has been reported in the
literature by Zota et al. [17] In contrast to our patient, the
patient reported by Zota et al. did not evolve in to acute
myeloid leukemia, albeit the acquisition of FIP1L1-
PDGFRA fusion was considered a feature of disease evolu-
tion. Initiation of imatinib resolved eosinophilia but did
not effectively improve other counts, and the patient sub-
sequently progressed to CMML-2 and developed extrame-
dullary disease in abdominal lymph nodes; she succumbed
in 10 months. A case series from Germany described five
patients with FIP1L1- PDGFRA who presented with AML
and eosinophilia, but no history of antecedent myeloidmalignancy was reported for any of the patients [18].
A summary of case reports describing PDGFRA rear-
rangements arising in patients with myeloid neoplasms
commonly not associated with such rearrangements is
provided in Table 2. All patients received imatinib therapy
and achieved at least a hematologic response. One patient
got sorafenib and another got dasatinib after acquiring
resistance to imatinib. Two of eight patients maintained
molecular response, while two maintained hematologic re-
sponse at last reported follow up. Notably, clonal acquisi-
tion of FIP1L1-PDGFRA has not been reported in the
setting of acute myeloid leukemia evolving from CMML.
Our case highlights the importance of assessing for
PDGFRA rearrangement in myeloid neoplasms with de
novo or subsequently acquired eosinophilia. The identifi-
cation of the FIP1L1- PDGFRA fusion gene is significant
since imatinib has excellent efficacy at low doses (100-
400 mg daily) in FIP1L1-PDGFRA-positive neoplasms
[2,5]. Of note, due to the 250-fold lower IC50 as compared
to BCR-ABL, reports suggest that even once weekly doses
of imatinib are adequate in the setting of FIP1L1-PDGFRA
[3]. However, these responses are eventually lost due to
emergence of an imatinib-resistant T614I mutation in the
ATP-binding site of PDGFRA [9]. In our patient, the abil-
ity to induce a complete remission using imatinib at a time
when the patient was unresponsive to chemotherapy in-
duction permitted subsequent allogeneic SCT and an en-
suing durable remission as of last follow up.
Conclusion
We describe a case report of a patient who transformed
from CMML to AML which was refractory to standard
chemotherapy. Emergence of peripheral and bone mar-
row hypereosinophilia during this transformation led to
suspicion of presence of FIP1L1-PDGFRA rearrange-
ment, which was confirmed by FISH and RT-PCR.
Treatment with imatinib led to a complete remission
and permitted allogeneic SCT therapy.
Endnote
The identification of new onset of eosinophilia in acute
myeloid leukemia arising in a patient with chronic mye-
lomonocytic leukemia might indicate acquisition of
imatinib-responsive FIP1L1-PDGFRA rearrangement.
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